Meprobamate
PronunciationPronunciation: meh-pro-BAM-ate
Class: Antianxiety agent
Trade Names
Meprobamate
- Tablets 200 mg
- Tablets 400 mg
Pharmacology
Produces CNS depressant action at multiple sites, including thalamic and limbic systems.
Pharmacokinetics
Absorption
Meprobamate is well absorbed. T max is 1 to 3 h.
Distribution
Meprobamate protein binding is approximately 15%.
Metabolism
80% to 92% is metabolized in the liver.
Elimination
90% is excreted renally and approximately 10% in feces. Plasma t ½ is 6 to 14 h for a single dose and 24 to 48 h for chronic dosing.
Indications and Usage
Management of anxiety.
Contraindications
Hypersensitivity to meprobamate or related compounds, such as carisoprodol; acute intermittent porphyria.
Dosage and Administration
AdultsPO 1.2 to 1.6 g/day in 3 to 4 divided doses (max, 2.4 g/day).
Children 6 to 12 yr of agePO 100 to 200 mg 2 to 3 times daily.
Storage/Stability
Store in dry, cool place.
Drug Interactions
Alcohol, CNS depressantsMay produce additive CNS depression.
Laboratory Test Interactions
None well documented.
Adverse Reactions
Cardiovascular
Palpitations; tachycardia; syncope; hypertension; hypotensive crisis; arrhythmias.
CNS
Drowsiness; ataxia; euphoria; slurred speech; dizziness; headache; paradoxical excitement.
GI
Nausea; vomiting; diarrhea.
Hematologic
Leukopenia; thrombocytopenia; agranulocytosis; aplastic anemia.
Miscellaneous
Hypersensitivity (eg, rash, itching, fever, chills, edema, bronchospasm, anaphylaxis, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, bullous dermatitis); exacerbation of porphyria symptoms.
Precautions
Pregnancy
Category D . Use with extreme caution, if at all.
Lactation
Excreted in breast milk.
Children
Do not give to children younger than 6 yr of age; safety and efficacy not established.
Elderly
Use lowest effective dose to avoid oversedation.
Hypersensitivity
Usually seen between first and fourth dose in patients without previous exposure.
Renal Function
Use drug with caution to avoid accumulation in patients with renal function impairment.
Hepatic Function
Use drug with caution to avoid accumulation in patients with hepatic function impairment.
Dependence
Physical and psychological dependence and abuse may occur. Avoid prolonged use, especially in patients prone to addiction. Abrupt discontinuation after prolonged or excessive use may precipitate withdrawal symptoms with risk of seizures.
Debilitated patients
Use lowest effective dose to avoid oversedation.
Overdosage
Symptoms
Drowsiness, lethargy, stupor, ataxia, coma, shock, vasomotor and respiratory collapse, death.
Patient Information
- Instruct patient not to crush or chew tablets or capsules.
- Advise patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness.
- Instruct patient to avoid intake of alcoholic beverages or other CNS depressants.
- Explain potential adverse reactions, and encourage patient to notify health care provider if signs of itching, rash, fever, drowsiness, dizziness, difficulty walking, nausea, vomiting, diarrhea, palpitations, shortness of breath, or sore throat occur.
- Caution patient to change position slowly to minimize orthostatic hypotension.
- Caution patient not to discontinue taking drug abruptly because doing so may precipitate preexisting symptoms or withdrawal reactions.
- Advise women that if they become pregnant or intend to become pregnant to consult their health care provider about continued use of this drug.
Copyright © 2009 Wolters Kluwer Health.
More Meprobamate resources
- Meprobamate Prescribing Information (FDA)
- Meprobamate Monograph (AHFS DI)
- meprobamate Advanced Consumer (Micromedex) - Includes Dosage Information
- meprobamate Concise Consumer Information (Cerner Multum)
- meprobamate MedFacts Consumer Leaflet (Wolters Kluwer)




